Role of protein contaminants in the immunogenicity of alginates
Source abstract
Abstract
Abstract Alginate is widely used for cell microencapsulation and transplantation. There is a lack of standardization of alginate purity and composition. In a previous study, we compared different alginate purification methods and concluded that polyphenol and endotoxin contaminants were eliminated efficiently but residual protein contaminants persisted with all of the methods under evaluation. The objective of this study was to test the hypothesis that residual proteins play a role in the immunogenicity of certain alginate preparations. Using preparative size exclusion chromatography (SEC) and a large scale purification protocol that was derived from the findings obtained with SEC, we substantially decreased the protein content of alginate preparations. When implanted into mouse peritoneum, barium alginate beads made of alginates that were purified using SEC or the derived large scale protocol induced significantly less pericapsular cell adhesion than those made with control alginates. In conclusions, these results suggest that removing residual protein contamination may decrease the immunogenicity of certain alginate preparations. The measurement of proteins could be used as a screening method for evaluating alginate preparations. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2010
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · 3D Printing in Biomedical Research · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. 10.1126/science.677662810.1126/science.6776628 ↗
2. 10.1016/j.tibtech.2003.11.00410.1016/j.tibtech.2003.11.004 ↗
3. 10.2337/diab.40.11.151110.2337/diab.40.11.1511 ↗
4. Hallé JP · 2009
5. 10.1016/j.biomaterials.2006.02.04810.1016/j.biomaterials.2006.02.048 ↗
6. 10.2174/18715220677635994810.2174/187152206776359948 ↗
7. 10.1021/bm800357210.1021/bm8003572 ↗
8. 10.1016/j.biomaterials.2007.10.04510.1016/j.biomaterials.2007.10.045 ↗
9. 10.1002/bit.26033011110.1002/bit.260330111 ↗
10. 10.1002/bit.26033011210.1002/bit.260330112 ↗
11. Transplantation of microencapsulated islets in rats: Evidence for induction of fibrotic overgrowth by islet alloantigens released from microcapsules
12. 10.1016/S0142-9612(03)00299-010.1016/S0142-9612(03)00299-0 ↗
13. An immunologic basis for the fibrotic reaction to implanted microcapsules
14. de Vos P · 87
15. 10.1080/026520403100014079610.1080/0265204031000140796 ↗
16. 10.1007/BF0040092210.1007/BF00400922 ↗
17. 10.1002/elps.115013015610.1002/elps.1150130156 ↗
18. 10.1007/BF0017332110.1007/BF00173321 ↗
19. 10.1007/s00125005067310.1007/s001250050673 ↗
20. 10.1111/j.1749-6632.1997.tb52197.x10.1111/j.1749-6632.1997.tb52197.x ↗
21. 10.2337/diabetes.50.8.169810.2337/diabetes.50.8.1698 ↗
22. 10.1089/ten.tea.2008.011810.1089/ten.tea.2008.0118 ↗
23. 10.1097/01.TP.0000150021.06027.DC10.1097/01.TP.0000150021.06027.DC ↗
24. 10.1016/S0142-9612(02)00319-810.1016/S0142-9612(02)00319-8 ↗
25. 10.1007/s00253005001210.1007/s002530050012 ↗
26. 10.1111/j.1749-6632.2001.tb03833.x10.1111/j.1749-6632.2001.tb03833.x ↗
27. 10.1172/JCI11892910.1172/JCI118929 ↗
28. Lymphoid activation by different crude alginates and the effect of purification
29. 10.2337/diabetes.54.3.68710.2337/diabetes.54.3.687 ↗
30. 10.1002/jbm.a.3054110.1002/jbm.a.30541 ↗
31. Barium‐alginate beads for immunoisolated transplantation of islets of Langerhans
32. 10.1177/09636897940030050310.1177/096368979400300503 ↗
33. 10.1016/j.biomaterials.2005.08.02710.1016/j.biomaterials.2005.08.027 ↗
34. European Pharmacopoeia. · 1997
35. 10.1111/j.1749-6632.2001.tb03832.x10.1111/j.1749-6632.2001.tb03832.x ↗